Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study

Tumor necrosis factor (TNF), an anti-angiogenic agent in cancer treatment, is limited to isolated limb perfusion due to systemic toxicities. We previously prepared a TNF mutant (rmhTNF) that significantly improved responses in lung cancer patients and exhibited a promising safety profile in phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaowen, Song, Yang, Zhang, Kuo, Shang, Lei, Gao, Yuan, Zhang, Wei, Xue, Xiaochang, Jia, Huimin, Geng, Jian, Zhou, Wei, Dang, Yazheng, Li, Enxiao, Ti, Xinyu, Fan, Fulin, Zhang, Yingqi, Li, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404801/
https://www.ncbi.nlm.nih.gov/pubmed/25897826
http://dx.doi.org/10.1038/srep09918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404801/
https://www.ncbi.nlm.nih.gov/pubmed/25897826
http://dx.doi.org/10.1038/srep09918

Ejemplares similares